Omega Fund Management, LLC Long-Term Concentrated

Location: Boston, MA

CIK: 0001637359 · Show all filings

Period: Q2 2020 (← Previous) (Next →)

Filing Date: Aug 17, 2020

Total Value: $366M (100.0% shares, 0.0% debt)

Holdings (15)

REPL Replimune Group 36.1%

Value $132M Shares 5,344,971 Est. Cost $17.40 Unrealized +1.6%

— Morphic Holding 22.0%

Value $80.49M Shares 2,975,582 Est. Cost $19.82 Unrealized —

GOSS Gossamer Bio 11.8%

Value $43.17M Shares 3,320,608 Est. Cost $20.85 Unrealized -39.7%

ARQT Arcutis Biothereapeutics 7.0%

Value $25.54M Shares 844,680 Est. Cost $26.87 Unrealized +7.6%

IMUX Immunic 4.5%

Value $16.62M Shares 1,371,494 Est. Cost $13.14 Unrealized -22.6%

— Paratek Pharmaceuticals 3.7%

Value $13.59M Shares 2,602,739 Est. Cost $34.18 Unrealized —

— ESSA Pharma 2.5%

Value $9.284M Shares 1,497,448 Est. Cost $3.14 Unrealized —

TRVI Trevi Therapeutics 2.5%

Value $9.053M Shares 1,375,907 Est. Cost $8.20 Unrealized -57.1%

BEAM Beam Therapeutics 2.3%

Value $8.479M Shares 302,821 Est. Cost $21.73 Unrealized -0.8%

— Cidara Therapeutics 2.0%

Value $7.399M Shares 2,005,249 Est. Cost $5.64 Unrealized —

— ObsEva 1.6%

Value $5.886M Shares 999,364 Est. Cost $9.76 Unrealized —

— FibroGen 1.4%

Value $5.295M Shares 130,646 Est. Cost $27.34 Unrealized —

— Jounce Therapeutics 1.0%

Value $3.657M Shares 529,965 Est. Cost $21.99 Unrealized —

— Prevail Therapeutics 0.8%

Value $2.794M Shares 187,538 Est. Cost $13.20 Unrealized —

— Pieris Pharmaceuticals 0.6%

Value $2.327M Shares 750,741 Est. Cost $1.83 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
REPL	Replimune Group	5,344,971	$132M	36.1%	$17.40	+1.6%	Common Stock	76029N106
—	Morphic Holding	2,975,582	$80.49M	22.0%	$19.82	—	Common Stock	61775R105
GOSS	Gossamer Bio	3,320,608	$43.17M	11.8%	$20.85	-39.7%	Common Stock	38341P102
ARQT	Arcutis Biothereapeutics	844,680	$25.54M	7.0%	$26.87	+7.6%	Common Stock	03969K108
IMUX	Immunic	1,371,494	$16.62M	4.5%	$13.14	-22.6%	Common Stock	4525EP101
—	Paratek Pharmaceuticals	2,602,739	$13.59M	3.7%	$34.18	—	Common Stock	699374302
—	ESSA Pharma	1,497,448	$9.284M	2.5%	$3.14	—	Common Stock	29668H708
TRVI	Trevi Therapeutics	1,375,907	$9.053M	2.5%	$8.20	-57.1%	Common Stock	89532M101
BEAM	Beam Therapeutics	302,821	$8.479M	2.3%	$21.73	-0.8%	Common Stock	07373V105
—	Cidara Therapeutics	2,005,249	$7.399M	2.0%	$5.64	—	Common Stock	171757107
—	ObsEva	999,364	$5.886M	1.6%	$9.76	—	Common Stock	H5861P103
—	FibroGen	130,646	$5.295M	1.4%	$27.34	—	Common Stock	31572Q808
—	Jounce Therapeutics	529,965	$3.657M	1.0%	$21.99	—	Common Stock	481116101
—	Prevail Therapeutics	187,538	$2.794M	0.8%	$13.20	—	Common Stock	74140Y101
—	Pieris Pharmaceuticals	750,741	$2.327M	0.6%	$1.83	—	Common Stock	720795103